Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard


The Cancer Vanguard is a bold initiative setup to take leadership in the delivery of the National Cancer Strategy – Achieving World-Class Cancer Outcomes published in 2015 with a key aim of designing and implementing new and increasingly patient-centric models of care in cancer that can benefit and be adopted by the wider national cancer system.

In summer 2016, the Cancer Vanguard medicines optimisation team launched the ‘Pharma Challenge’ as an opportunity for the pharma and life sciences industry to identify innovative ways in which it could work in partnership with the NHS to improve the effective use of NHS resources, enhance the NHS’ understanding of the patient experience and make medicines optimisation part of routine practice. Four projects were taken forward, including a partnership between the Cancer Vanguard, QuintilesIMS, Merck and uMotif.

This unique example of partnership working across the health system is focussed on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

In this webinar, QuintilesIMS in partnership with pharmaphorum have assembled some of the leaders from the Cancer Vanguard project to explain how this innovative partnership between the pharmaceutical industry and the Cancer Vanguard was enabled and how through this collaboration the pharmaceutical industry is able to be a true partner in the development of new models of care.

Key themes

  • How can the pharmaceutical industry engage with the NHS in a genuine partnership?
  • How can pharmaceutical companies benefit from investing their time to help the NHS to deliver their efficiency programmes and new models of care?
  • How can the Cancer Vanguard use data driven insights to improve care?
  • How does the Cancer Vanguard point to pharma supporting positive patient outcomes via innovative uses of data and technology?
  • Can NHS-pharma relations move on from medicines optimisation to partnership of pathway optimisation?

Why watch the webinar?

The webinar brings together key stakeholders from the NHS, pharma industry and QuintilesIMS, who provide data, analysis and policy insights to provide a clear picture of what will be a highly influential pilot of new models of care for the health service.

The live webinar takes place on Monday 6th November at 12.30 GMT/13.30 CET. To register to view the webinar, please click here or on the button above/below.

Steve Jowett, Country lead for Health System Engagement, QuintilesIMS
Stephen leads the creation of propositions and partnerships, for QuintilesIMS UK, across the health system and is passionate about enabling collaboration to take place that advances healthcare and improves outcomes for patients. He has led and delivered dozens of technologically enabled transformation projects at the front line of care both at QuintilesIMS and in previous roles as deputy practice lead of Dell Services’ Healthcare Consulting Practice across EMEA. An information and business analyst by degree training, Stephen has also worked in the NHS as a business analyst and transformation lead

Rob Duncombe, Chief Pharmacist, The Christie NHS Foundation Trust
Robert is Director of Pharmacy at The Christie NHS Foundation Trust in Manchester, appointed in September 2012. He has a passion for improving medicines optimisation in cancer patients and helping patients to get the best from their cancer medicines, and ensuring the NHS gets the best value from this investment.
He is a member of the national Medicines Optimisation Clinical Reference Group (CRG) and also Chair of the Hospital expert Advisory Group of Royal Pharmaceutical Society; a committee member of the British Oncology Pharmacy Association; Joint Chair of the Hospital Pharmacy Transformation Programme for Manchester, and Chair of the Cancer Vanguard Medicines Optimisation work-stream Board.

Keir Woods, Oncology Business Unit Head, UK & Ireland, Merck

Keir Woods is Oncology Business Unit Head for Merck UK and Ireland.  A strong strategic thinker with focus on execution and a track record of delivering business transformation, he has over 20 years’ experience in a variety of global, regional and country leadership roles. Since 2015, Keir has worked with relentless ambition to strengthen Merck’s UK and Ireland oncology footprint, securing two positive  NICE appraisals for Erbitux (cetuximab), building Merck’s collaboration with key NHS stakeholders, and repositioning the UK and Ireland at the heart of Merck’s oncology R&D strategy.

Mike Ringe, NHS Strategy and Access Manager at The Association of the British Pharmaceutical Industry (ABPI)

Mike is NHS Engagement Partner (London) and Specialised Commissioning lead at the Association of the British Pharmaceutical Industry. His role is focused on working with ABPI members and the NHS (at both the national and regional level) to create better and more productive routes for collaborative working to deliver transformational change and improve patient outcomes. Mike joined the ABPI in late 2012 after a long career in the NHS,  initially in a community Trust before becoming Director of Commissioning at a PCT for some 7 years.  Following one of many NHS reorganisations, he joined Roche Products as a member of their Strategic and Funding Capacity team, before returning to the NHS in 2009 as a Director and subsequently  Chief Officer of a PBC group and then Chief Operating Officer of a shadow CCG, taking it through authorisation before joining the ABPI.  As such Mike brings a rare mix of senior NHS and industry experience.



Paul TunnahDr. Paul Tunnah, CEO, pharmaphorum
Paul Tunnah is CEO and Founder of pharmaphorum media, which facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. It combines industry-leading content and social media engagement services with the globally recognised news, information and insight portal, working with pharmaceutical companies, service providers and broader healthcare organisations to help communicate their thought leadership and connect them with relevant stakeholders.